deltatrials
Completed PHASE3 NCT00031096

Comparison of Efficacy and Safety of Azelaic Acid 15% Gel With Its Vehicle in Subjects With Mild to Moderate Acne

A 12-week, Randomized, Double-blind, Multicenter Study Comparing the Clinical Efficacy and Safety of Azelaic Acid 15% Gel (SH H 655 BA) With Its Vehicle (SH H 655 PBA) in Patients With Mild to Moderate Acne.

Sponsor: Bayer

Conditions Acne Vulgaris
Interventions Azelaic Acid Gel 15% (Finacea, BAY39-6251) Vehicle gel (SH H 655 PBA)
Updated 8 times since 2017 Last updated: Jun 8, 2023 Started: Jan 31, 2002 Primary completion: Jul 31, 2002 Completion: Jul 31, 2002

A PHASE3 clinical study on Acne Vulgaris, this trial is completed. The trial is conducted by Bayer and has accumulated 8 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jul 2023 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2023 [monthly]

    Completed PHASE3

  5. May 2020 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 3 earlier versions

  1. Jun 2018 — May 2020 [monthly]

    Completed PHASE3

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Jan 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bayer
  • LEO Pharma
Data source: LEO Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States, Bay Shore, United States, Boulder, United States, Bryan, United States, Cincinnati, United States, Hershey, United States, Knoxville, United States, Lexington, United States, Mobile, United States, Newnan, United States and 6 more location s